Apply the highest standards of urological care

Awards

To view all past Award Winners, please click here.


SIU 2021 and 2020 Mostafa M. Elhilali Award

Mark EMBERTON
Mark
EMBERTON
UNITED KINGDOM

Anthony ATALA
Anthony
ATALA
USA

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Anthony ATALA

Anthony ATALA

USA

Anthony Atala, M.D., is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of the Department of
Urology at Wake Forest University. His work focuses on growing human cells, tissues and organs. Dr Atala works with several journals and serves in various roles, including Editorin-Chief of: Stem Cells- Translational Medicine, and BioPrinting; Section Editor for Urology Survey in the Journal of Urology; and is on the Editorial Board of 11 journals. Fifteen applications of technologies developed in Dr Atala’s laboratory have been used clinically. He is the editor of 22 books, has published more than 800 journal articles
and has applied for or received over 250 national and international patents.

Dr Atala was elected to the National Academy of Medicine, and is a recipient of the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society; the Edison Science/Medical Award; the R&D Innovator of the Year Award; and the Smithsonian Ingenuity Award. Dr. Atala’s work was listed twice as Time Magazine’s top 10 medical breakthroughs of the year, and was ranked by the Project Management Institute as one of the top 10 most impactful biotech projects from the past 50 years. Dr Atala was named by Scientific American as one of the world’s most influential people in biotechnology, by U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, by Life Sciences Intellectual Property Review as one of 50 key influencers in the life sciences intellectual property arena, and by Nature Biotechnology as one of the top 10 translational researchers in the world.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


2021 and 2020 Félix Guyon Medal

Peter HAMMERER
Peter
HAMMERER
GERMANY

Badrinath KONETY
Badrinath
KONETY
USA

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Badrinath KONETY

Badrinath KONETY

USA

Badrinath R. Konety, M.D., M.B.A., is the Henry P Russe Dean, Rush Medical College and Senior Vice President of Clinical Affairs at the Rush System for Health, Rush University as well as Professor of Urology. He is the former Chair of the Department of Urology, Associate Director for Clinical Affairs of the Masonic Cancer Center at the University of Minnesota and Vice Dean for Clinical Affairs and CEO of University of Minnesota Physicians.

Dr Konety completed his residency and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He also received an MBA from the University of Pittsburgh Katz School of Business. Dr. Konety also completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center. He has authored or co-authored 300 peer reviewed publications and numerous book chapters as well as editing books on bladder cancer. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society and Center for Disease Control. He has received the Jahnigen Career Development Scholar Award and the Ferdinand Valentine fellowship. He is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Société Internationale D’Urologie (SIU) and the American Association of Genitourinary Surgeons. He is the Past President of te SIU and the Society of Academic Urology and is an Associate Editor of the Journal of Urology. He has been recognized for several years by the Best Doctors of America and Top Doctors of America.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


SIU 2021 and 2020 Albert Schweitzer Award

Narmada P. GUPTA
Narmada P.
GUPTA
INDIA

Serigne Magueye GUEYE
Serigne Magueye
GUEYE
SENEGAL

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Serigne Magueye GUEYE

Serigne Magueye GUEYE

Senegal

Serigne Magueye Gueye, M.D., is Professor of Surgery / Urology, University Cheikh Anta DIOP (UCAD) and Head of Urology and Chief Medical Officer Grand Yoff General Hospital. He is Director of IFRU-SF (www.ifrusf.org) a non-profit organization dedicated to building capacity and developing research in Urology throughout Africa. He is former Fulbright Scholar, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Dr Gueye is an active clinician, trainer and researcher. Co-founder of the Men of African Descent and Carcinoma of the Prostate Consortium (MADCAP), he is PI and CO-PI in many research projects. Past-President of African Organization of Research and Training in Cancer (AORTIC) and the Pan African Urological Surgeons Association (PAUSA), he is President-Elect of the West African College of Surgeons (WACS) and serves on numerous national and international advisory boards.

Dr Gueye is the Director of the SIU-accredited Dakar Center offering fellowship training in General urology, endourology, uro-oncology and reconstructive and female urology of
residents from Africa and the rest of the World. Dr Gueye has been an active member of the SIU for several years and formerly served as a member of the SIU Board of Directors
as the Membership and International Relations Lead for Africa and the Middle East. For his work, Dr Gueye has been awarded many national and international medals in
Senegal, France, Chad, Rwanda including the United Nations’ Medal for Peace in Rwanda.

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


2021 Distinguished Career Award

Hassan ABOL-ENEIN
Hassan
ABOL-ENEIN
EGYPT

Margit FISCH
Margit
FISCH
GERMANY

Ates KADIOGLU
Ates
KADIOGLU
TURKEY

Alexey G. MARTOV
Alexey G.
MARTOV
RUSSIA

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


2021 SIU-Innovators Award

Jeremy TEOH
Jeremy
TEOH
HONG KONG

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


2021 Distinguished Partner Award

Coloplast Interventional Urology
Coloplast Interventional
UROLOGY

Mark EMBERTON

Mark EMBERTON

UNITED KINGDOM

Mark Emberton, MB BS, FRCS (Urology), MD, FMedSci, is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.            

Dr. Emberton’s clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).                                

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen’s Birthday Honours for his services to prostate cancer research.

Peter HAMMERER

Peter HAMMERER

GERMANY

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the fi eld of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d’Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientifi journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level. After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men’s health.

Narmada P. GUPTA

Narmada P. GUPTA

INDIA

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientifi c papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d’Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014). 

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005. 

Hassan ABOL-ENEIN

Hassan ABOL-ENEIN

EGYPT

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.

Margit FISCH

Margit FISCH

GERMANY

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientifi c interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.
Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is
a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more then 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

Ates KADIOGLU

Ates KADIOGLU

TURKEY

Ateş Kadıoğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadıoğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadıoğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie’s Disease Committee in the 4th International Erectile and Sexual Function consultation.

 

Alexey G. MARTOV

Alexey G. MARTOV

RUSSIA

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute’s vice-president. In 1993, he earned his PhD degree in “Endourological Treatment of Upper Urinary Tract Diseases.” In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov’s specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

 

Jeremy TEOH

Jeremy TEOH

HONG KONG

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.

Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d’Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.

Coloplast Interventional Urology

Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones, and erectile dysfunction. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.


 

 

SIU 2021 On Demand
B2B GU Cancers Triad 2021 On Demand
MH B2B on demand
Follow Us

Twitter feed
JOIN THE SIU COMMUNITY



Corporate Sponsors

Society Contributors